Skip to main content

Biocartis IVD NRAS Test for Colorectal Cancer

Biocartis has launched its Idylla NRAS Mutation Test. The CE-marked IVD assay joins the company's existing Idylla NRAS-BRAF Mutation Test, allowing for more flexibility in geographies where BRAF testing for metastatic colorectal cancer patients is not reimbursed. According to Biocartis, the NRAS-only assay detects 18 mutations directly from a single slice of FFPE tumor tissue in approximately two hours, with less than two minutes hands-on time.
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.